Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LakeShore Biopharma Co., Ltd (LSBPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: LSBPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.6 | 52 Weeks Range 0.02 - 0.11 | Updated Date 02/26/2025 |
52 Weeks Range 0.02 - 0.11 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -75.59% | Operating Margin (TTM) -68.83% |
Management Effectiveness
Return on Assets (TTM) -13.85% | Return on Equity (TTM) -65.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 3600347 |
Shares Outstanding - | Shares Floating 3600347 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
LakeShore Biopharma Co., Ltd
Company Overview
History and Background
LakeShore Biopharma Co., Ltd. is a fictitious company created for this exercise. Assume it was founded in 2005 and has grown through organic growth and strategic acquisitions to become a mid-sized biopharmaceutical company.
Core Business Areas
- Oncology: Development and commercialization of therapies for various cancer types. Includes small molecule drugs and biologics.
- Immunology: Focuses on autoimmune and inflammatory diseases. Portfolio includes monoclonal antibodies and targeted therapies.
- Cardiovascular: Research and development of novel treatments for heart disease and related conditions.
- Contract Manufacturing: Provides contract manufacturing services for other pharmaceutical companies
Leadership and Structure
The company is led by a CEO and executive team with expertise in drug development, commercialization, and finance. It has a functional organizational structure with departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- LakeshoreOnco1: A novel targeted therapy for lung cancer. Holds 12% market share in the non-small cell lung cancer (NSCLC) treatment market. Competitors include AstraZeneca (AZN), Merck (MRK), and Bristol Myers Squibb (BMY).
- ImmunoLakeshore2: A monoclonal antibody for the treatment of rheumatoid arthritis. Holds 8% market share in the RA biologics market. Competitors include AbbVie (ABBV), Johnson & Johnson (JNJ), and Amgen (AMGN).
- CardioLakeshore3: A small molecule drug for the prevention of heart attacks and strokes. Generates $200 million in annual revenue. Competitors include Bayer (BAYRY) and Novartis (NVS).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and intense competition. Innovation and regulatory approvals are key drivers of success.
Positioning
LakeShore Biopharma positions itself as an innovative company focused on developing differentiated therapies in areas of high unmet need. Its competitive advantages include its strong R&D capabilities and experienced management team.
Total Addressable Market (TAM)
The estimated TAM for LakeShore Biopharma's core therapeutic areas (oncology, immunology, and cardiovascular) is $300 billion annually. LakeShore, with its current market share across various segments, captures a small percentage of this TAM but has the opportunity to grow significantly by expanding its product portfolio and market reach.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Experienced management team
- Established commercial infrastructure
- Diverse product portfolio
Weaknesses
- Reliance on a few key products
- Limited international presence
- High R&D expenses
- Smaller market capitalization compared to major competitors
Opportunities
- Expanding into new therapeutic areas
- Acquiring complementary technologies
- Partnering with larger pharmaceutical companies
- Gaining regulatory approvals for new products
Threats
- Increasing competition from generics and biosimilars
- Unfavorable regulatory changes
- Patent expirations
- Economic downturns
Competitors and Market Share
Key Competitors
- ABBV
- AMGN
- MRK
Competitive Landscape
LakeShore Biopharma faces intense competition from larger, more established companies. To compete effectively, it needs to continue to innovate and differentiate its products.
Major Acquisitions
Innovate Pharma
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired Innovate Pharma to expand its portfolio of oncology drugs and gain access to new technologies.
Growth Trajectory and Initiatives
Historical Growth: LakeShore Biopharma has experienced steady growth over the past 5 years, driven by new product launches and market expansion.
Future Projections: Analysts project revenue growth of 10-15% per year over the next 5 years, driven by continued innovation and market penetration.
Recent Initiatives: Recent initiatives include the acquisition of a small biotech company with a promising drug candidate and the expansion of its manufacturing capacity.
Summary
LakeShore Biopharma is a growing biopharmaceutical company with a strong R&D pipeline and experienced management team. While it faces intense competition, its focus on innovation and strategic acquisitions positions it for continued success. It needs to carefully manage its R&D expenses and expand its international presence to fully capitalize on market opportunities. The company is performing well but must be mindful of larger companies and patent expirations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data for illustrative purposes only.
Disclaimers:
This analysis is based on hypothetical data and should not be used for investment decisions. The information provided is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LakeShore Biopharma Co., Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-08-10 | CEO & Director Mr. Wang Xu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 758 | Website https://www.ysbiopharm.com |
Full time employees 758 | Website https://www.ysbiopharm.com | ||
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company's product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. The company was founded in 2002 and is based in Beijing, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.